Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

CalAmp Corp. (CAMP), athenahealth, Inc (ATHN), Apple Inc. (AAPL): 3 Essential Rules For Aggressive Growth Investing

Page 1 of 2

Every intelligent investor’s portfolio must devote assets to aggressive growth.

No exceptions.

CalAmp Corp. (NASDAQ:CAMP)Because finding a winning aggressive growth stock isn’t easy, I want to share with you how I do it…

I look for companies with products, technologies or other innovations that materially change the baseline assumptions for doing business in an industry.

These are the companies seeking to hit one out of the park by finding The Next Big Thing.

You see, I have a knack for this. I don’t mean to brag, but in my nearly five years with StreetAuthority, I’ve picked more triple-digit gainers than just about any other analyst.

Last August, for example, I recommended AuthenTec, a company beginning to dominate themarket for biometric readers — fingerprint scanners on personal electronic devices.

Not too long afterward, Apple Inc. (NASDAQ:AAPL) agreed to buy the company.

Readers of Game Changing Stocks who followed my advice saw a total gain of 228%.

Another example: CalAmp Corp. (NASDAQ:CAMP), a maker of wireless communications hardware, rose 290% after I recommended it.

That’s just the tip of the iceberg.

And I’ve done it by following three simple rules that any investor can follow.

Rule No. 1. Be realistic to the point of hyper-rationality
I lost track years ago of how many clinical trials I’ve read about various drugs.

But do you know something? At the end of every report, I wanted to buy every one of the stocks behind those drugs. The studies are detailed and educational. They set up the problem and then offer a unique solution. The science, the explanation, the data and the financials are always very appealing.

But these early-stage drug-development companies are very risky. Heck, they are damn risky. No matter how good the initial trials look, there is no guarantee of approval, and a negative action by the Food and Drug Administration can cut a small drug company’s stock price in half quicker than you can say Jack Robinson.

The other side of that coin, of course, is that the FDA (or one of its international counterparts) could rule in the drug’s favor, in which case the little company’s stock price chart resembles a space shuttle launch.

Let me quantify this for you. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), the world’s 28 leading drug companies spend about $50 BILLION a year alone looking for new drugs.

But the FDA approved all of 39 drugs in 2012 — not even one a week. The PhRMA says only 1 in 10,000 of the compounds studied by drug companies becomes a product for sale on the pharmacy shelf.

Page 1 of 2
Loading Comments...